Background: Atrial conduction abnormalities in patients with scleroderma have not been evaluated in terms of P wave duration, P wave dispersion (Pd) and electromechanical coupling measured by tissue Doppler echocardiography. Methods: Twenty-four patients with scleroderma and 24 control subjects underwent resting electrocardiogram (ECG), M mode and tissue Doppler echocardiography. The P wave duration was calculated in all leads of the surface ECG. The difference between the maximum (Pmax) and minimum P wave duration was calculated and defined as Pd. Interatrial and intraatrial electromechanical delays were measured with tissue Doppler tissue echocardiography. Results: The left ventricular dimensions, fractional shortening, and left atrial diameter did not differ between the patients and the controls. Pd and Pmax were significantly higher in patients with scleroderma compared with controls: 51 ± 17 versus 28 ± 7 ms (p < 0.01) and 109 ± 10 versus 93 ± 6 ms (p < 0.01), respectively. There was a delay between the onset of the P wave on surface ECG and the onset of the late diastolic wave (A wave; PA) obtained by tissue Doppler echocardiography in patients with scleroderma compared with controls measured at lateral septal annulus (lateral PA; 122 ± 8 vs. 105 ± 7 ms, p = 0.001), septal mitral annulus (104 ± 11 vs. 93 ± 10 ms, p = 0.01) and tricuspid annulus (right ventricular PA; 71 ± 9 vs. 64 ± 7 ms, p = 0.05). Interatrial conduction time (lateral PA – right ventricular PA) was delayed in patients with scleroderma compared with controls (88 ± 13 vs. 76 ± 11 ms, p = 0.01). A positive correlation was detected between interatrial electromechanical delay (lateral PA – right ventricular PA) and Pd (r = 0.5, p = 0.03). Conclusion: Atrial conduction abnormalities as estimated with Pd and Pmax are significantly higher in patients with scleroderma compared with controls. There is a delay in both intraatrial and interatrial electromechanical coupling intervals in patients with scleroderma.

Keywords:
Scleroderma, P wave duration, Tissue Doppler echocardiography
1.
D’Angelo WA, Fries JF, Masi AT, Schulman LE: Pathologic observations in systemic sclerosis (scleroderma): study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969;46:428–440.
2.
Follansbee WP, Miller TR, Curtiss EI, et al: A controlled clinicopathologic study of myocardial fibrosis in systemic sclerosis (scleroderma). J Rheumatol 1990;17:656–662.
3.
Ridolfi RL, Bulkley BH, Hutchins GM: The cardiac conduction system in progressive systemic sclerosis: clinical and pathologic features of 35 patients. Am J Med 1976;61:361–366.
4.
Bulkley BH, Ridolfi RL, Salyer WR, Hutchins GM: Myocardial lesions of progressive systemic sclerosis: a cause of cardiac dysfunction. Circulation 1976;53:483–490.
5.
Follansbee WP, Curtiss EI, Medsger TA, et al: Physiologic abnormalities of cardiac function in progressive systemic sclerosis with diffuse scleroderma. N Engl J Med 1984;310:142–148.
6.
Butrous GS, Dowd PM, Milne J, Dymond DS, Caplin J, Camm AJ: Non-invasive assessment of early cardiac involvement in systemic sclerosis. Postgrad Med J 1985;61:679–684.
7.
Kostis JB, Seibold JR, Turkevich D, et al: Prognostic importance of cardiac arrhythmias in systemic sclerosis. Am J Med 1988;84:1007–1015.
8.
Clements PJ, Furst DE, Cabeen WR, Tashkin D, Paulus HE, Roberts NK: The relationship of arrhythmias and conduction disturbances to other manifestations of cardiopulmonary disease in progressive systemic sclerosis. Am J Med 1981;71:38–46.
9.
Roberts NK, Cabeen WR Jr, Moss J, Clements PJ, Furst DE: The prevalence of conduction defects and cardiac arrhythmias in progressive systemic sclerosis. Ann Intern Med 1981;94:38–40.
10.
Mizuno R, Fujimoto S, Nakano H, et al: Atrial conduction abnormalities in patients with systemic progressive sclerosis. Eur Heart J 1997;18:1995–2001.
11.
Ozer N, Yavuz B, Can I, et al: Doppler tissue evaluation of intra-atrial and interatrial electromechanical delay and comparison with P-wave dispersion in patients with mitral stenosis. J Am Soc Echocardiogr 2005;18:945–948.
12.
Boriani G, Diemberger I, Biffi M, et al: P wave dispersion and short-term vs late atrial fibrillation recurrences after cardioversion. Int J Cardiol 2005;101:355–361.
13.
Kose S, Aytemir K, Sade E, et al: Detection of patients with hypertrophic cardiomyopathy at risk for paroxysmal atrial fibrillation during sinus rhythm by P-wave dispersion. Clin Cardiol 2003;26:431–434.
14.
Dilaveris PE, Gialafos EJ, Sideris SK, et al: Simple electrocardiographic markers for the prediction of paroxysmal idiopathic atrial fibrillation. Am Heart J 1998;135:733–738.
15.
Fernandes F, Ramires FJ, Arteaga E, Ianni BM, Bonfa ES, Mady C: Cardiac remodeling in patients with systemic sclerosis with no signs or symptoms of heart failure: an endomyocardial biopsy study. J Card Fail 2003;9:311–317.
16.
Sackner MA, Heinz ER, Steinberg AJ: The heart in scleroderma. Am J Cardiol 1966;17:542–559.
17.
Tezcan UK, Amasyali B, Can I, et al: Increased P wave dispersion and maximum P wave duration after hemodialysis. Ann Noninvasive Electrocardiol 2004;9:34–38.
18.
Dogan A, Acar G, Gedikli O, et al: A comparison of P-wave duration and dispersion in patients with short-term and long-term atrial fibrillation. J Electrocardiol 2003;36:251–255.
19.
Szabo Z, Kakuk G, Fulop T, et al: Effects of haemodialysis on maximum P wave duration and P wave dispersion. Nephrol Dial Transplant 2002;17:1634–1638.
20.
Tsikouris JP, Kluger J, Song J, White CM: Changes in P-wave dispersion and P-wave duration after open heart surgery are associated with the peak incidence of atrial fibrillation. Heart Lung 2001;30:466–471.
21.
Dilaveris PE, Gialafos JE: P-wave dispersion: a novel predictor of paroxysmal atrial fibrillation. Ann Noninvasive Electrocardiol 2001;6:159–165.
22.
Keating RJ, Gersh BJ, Hodge DO, et al: Effect of atrial fibrillation pattern on survival in a community-based cohort. Am J Cardiol 2005;96:1420–1424.
23.
Vidaillet H, Granada JF, Chyou PH, et al: A population-based study of mortality among patients with atrial fibrillation or flutter. Am J Med 2002;113:365–370.
24.
Stewart S, Hart CL, Hole DJ, McMurray JJ: A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002;113:359–364.
25.
Montanes P, Lawless C, Black C, Oakley CM, Hughes G: The heart in scleroderma: noninvasive assessment. Clin Cardiol 1982;5:383–387.
26.
Follansbee WP, Curtiss EL, Rahko PS, et al: The electrocardiogram in systemic sclerosis (scleroderma): study of 102 consecutive cases with functional correlations and review of the literature. Am J Med 1985;79:183–192.
27.
Morelli S, Sgreccia A, Ferrante L, et al: Relationships between electrocardiographic and echocardiographic findings in systemic sclerosis (scleroderma). Int J Cardiol 1996;57:151–160.
28.
Rein A, O’Donnel CP, Colan SD, Marx GR: Tissue velocity Doppler assessment of atrial and ventricular electromechanical coupling and atrioventricular time intervals in normal subjects. Am J Cardiol 2003;92:1347–1350.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.